SCHEMBL16635684

SCHEMBL16635684

O=C(O)C1CCCCC1c1nc(-c2ccc(F)cc2)oc1-c1ccc(N2CCS(O)(O)CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 6/20 0.47
L3MBTL1 Q9Y468 1/20 0.39
S1PR1 P21453 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
NOTUM Q6P988 1/20 0.35
MAPT P10636 5/20 0.35
TP53 P04637 2/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
TSHR P16473 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
HPGD P15428 1/20 0.34
MAPK1 P28482 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16635996 1.00 CTSK (0.47) CTSKL3MBTL1S1PR1MEN1KMT2A
SCHEMBL16635997 0.93 CTSK (0.54) CTSKL3MBTL1S1PR1MEN1KMT2A
SCHEMBL16635685 0.93 CTSK (0.54) CTSKL3MBTL1S1PR1MEN1KMT2A
SCHEMBL16636476 0.90 CTSK (0.47) CTSKL3MBTL1MEN1KMT2AMAPT
SCHEMBL16635709 0.84 CTSK (0.70) CTSK
SCHEMBL16636475 0.82 CTSK (0.54) CTSKL3MBTL1MEN1KMT2AMAPT
SCHEMBL16635711 0.77 CTSK (0.79) CTSK
SCHEMBL16635943 0.76 CTSK (0.64) CTSK
SCHEMBL16635861 0.75 SMN1; SMN2 (0.38) CTSKTP53KDM4EALDH1A1HPGD
SCHEMBL16618096 0.73 CTSK (0.48) CTSKALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ CTSK 4/4885L3MBTL1 373/4885S1PR1 1363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.